DISPLAYTITLE:N-Phenylacetyl-L-prolylglycine ethyl ester
N-Phenylacetyl--prolylglycine ethyl ester is promoted as a nootropic and is a prodrug of cyclic glycine-proline. Other names include the brand name Noopept (Ноопепт), developmental code GVS-111; proposed INN omberacetam.
Its synthesis was first reported in 1996. It is orally available, as of 2017 its metabolism and elimination half-life were not well understood, and cycloprolylglycine has not been measured in humans following administration. In cell culture, cycloprolylglycine increases brain derived neurotrophic factor (BDNF).
It has been evaluated for neuroprotective effects in treating brain injuries and stroke.
One oft-cited study (originally published in Russian) conducted on rats, suggests that Noopept works via the "antioxidant effect, the anti-inflammatory action, and the ability to inhibit the neurotoxicity of excess calcium and glutamate